Published 13 days ago

Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Summary by CNBC

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.

0 Articles

All

Left

Center

Right

The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated12 days agoBias Distribution

100% Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)